Ablynx NV today announced that Dr Bo Jesper Hansen, acting as permanent representative of Orfacare Consulting GmbH, has decided to resign from the Board of Directors with immediate effect for personal reasons.
Having contributed to Ablynx’s recent M&A activities, and served on the Board since 2013, Dr Hansen will now focus on other opportunities. He will be succeeded by Dr Russell G. Greig, acting as a permanent representative of Greig Biotechnology Global Consulting Inc., who has been a non-executive Director of Ablynx since 2012, and has been unanimously elected by the Ablynx Board as the new Chairman.
Dr Greig is an industry veteran and is currently Chairman of AM Pharma and MedEye (The NL), Sanifit (Spain and the USA), eTheRNA (Belgium), and a non-executive Director of TiGenix (Belgium). Following a 28-year career at GSK where he held the positions of President of both GSK Pharmaceuticals International and SROne (the Venture Arm of GSK), Dr Greig has served as Chairman of Novagali (sold to Santen), Isconova (to Novavax), Syntaxin (to Ipsen), and as a Venture Partner at Kurma Life Sciences (France).
Dr Edwin Moses, Chief Executive Officer at Ablynx, commented: “We are very fortunate to have a very suitable successor for Bo Jesper, allowing for an orderly transition at this time. Russell knows the company extremely well and will be an important asset during the next months.”
Dr Russell Greig, commented: “I am delighted to accept this position, having worked with the Ablynx Board over the past five years. My goal will be to fully support the proposed acquisition of the Company by Sanofi as recommended by the Ablynx Board.”
From 7 February 2018, the composition of the Board of Ablynx is as follows:
• Russell Greig, Chairman of the Board, acting as permanent representative of Greig Biotechnology Global Consulting Inc.
• Edwin Moses, Director and Chief Executive Officer
• William Jenkins, Independent Director, acting as principal of William Jenkins Pharma Consulting
• Catherine Moukheibir, Independent Director
• Remi Vermeiren, Independent Director
• Lutgart Van den Berghe, Independent Director, acting as permanent representative of NV Feadon
• Hilde Windels, Independent Director, acting as permanent representative of Hilde Windels BVBA
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).